Anuj Gupta, MD, is an Associate Professor at the University of Maryland School of Medicine. An interventional cardiologist, he serves as director of the Cardiac Catheterization Laboratory at the University of Maryland School of Medicine. His primary focus is on the treatment of severe aortic stenosis in patients who are eligible for transcatheter aortic valve replacement (TAVR). In his role evaluating TAVR and related therapies, he is the site principal investigator for the PARTNER 2 trial, Galileo Trial, and a future low-risk, randomized trial for TAVR. In addition, he is involved in renal denervation studies, including the SYMPLICITY-HTN3 trial and Reduce HTN: Reinforce trial.
He is the Governor of the Maryland Chapter of the American College of Cardiology, the professional society for cardiologists and related cardiovascular specialists. He is a principal in the Maryland Academic Consortium for Percutaneous Coronary Intervention Appropriateness and Quality (MACPAQ), a joint initiative between Johns Hopkins University School of Medicine and the University of Maryland School of Medicine to create a system of external peer review for PCI in the state of Maryland. External peer review, a state requirement for providing PCI services, demonstrates that the hospitals in Maryland are providing appropriate, high-quality PCI services.
Dr. Gupta was named a "Top Doctor" in the specialty of Cardiology: Interventional by Baltimore magazine in 2016 and 2019.
His special interests include:
- Coronary artery disease
- Coronary revascularization
- Peripheral vascular disease
- Radial artery access interventions
- Renal denervation
- Transcatheter aortic valve replacement
